Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Zacks Investment Research - ATE upgareded to $28/share
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(57)
•••
Comment by TriumphSpitSixon Dec 09, 2020 1:17am
206 Views
Post# 32065080

RE:RE:RE:Zacks Investment Research - ATE upgareded to $28/share

RE:RE:RE:Zacks Investment Research - ATE upgareded to $28/shareI've made this point before also. It's not a 12-month price target. It should be $28/share TODAY.

Actuarial wrote: $28 is a conditional and discounted present value - conditional on successful FDA approval. In another word, it is the valuation as of today. When the time getting close to commercial launch, SP would be much higher than $28. Assume the discount rate being 5%, commercial launch date 2023, then the SP = $28 * 1.05^ (2023-2020) = $32.41. The higher discount rate, the higher SP would be when the time comes. And, I believe it is only the price of 346. Should we add 340 & 352 into the valucation, it can easily be doubled.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities